Companies
-
BMS blockbuster falls off patent cliff
- Mon Aug 3
Once a blockbuster, this anticoagulant just tumbled off the patent cliff – and it’s not the only one as LOEs generate $95M in annual PBS savings this month.
Read more -
Gilead gets reprieve in HIV court battle
- Mon Aug 3
Injunction gives Gilead a 12 month reprieve, saving the company’s $172 million HIV combination market on the PBS from generic predators.
Read more -
Pfizer calls out out-dated risk deals
- Fri Jul 31
When Health bureaucrats refused to renegotiate an appropriate deal for a stable PBS product, Pfizer was forced to call on PBAC to act as umpire.
Read more -
Career wisdom delivered straight from the Vial
- Fri Jul 31
When three school students accompanied me to Sanofi, Head of Travel Vaccines Christophe Vial impressed them (almost) as much as the spectacular Barangaroo view.
Read more -
Argenx bets big on autoimmune buy
- Wed Jul 29
US$2.2B buyout of Forte brings first‑in‑class coeliac contender into the Dutch pharma’s portfolio, and it has more still to spend.
Read more -
‘Phoenix’ leader to steer Australia’s mRNA rise
- Mon Jul 27
As Moderna’s mRNA facility in Melbourne prepares for lift‑off, Carolyn Tucek‑Szabo is perfectly prepared to guide it through this next phase.
Read more -
Commercial leader to guide LumaCina expansion
- Mon Jul 27
One of Australia’s few remaining pharma manufacturing facilities appoints a leader with strong experience to steer it through an aggressive expansion phase.
Read more -
Boehringer buddies up in patient input
- Mon Jul 27
Boehringer Ingelheim and leading patient groups launch Patient Input Buddy, an AI tool helping Australians share meaningful input in PBAC consultations.
Read more